FDA bans another Ranbaxy plant

Share this article:

Ranbaxy's US woes continue. The FDA announced Friday that it has now banned drugs from the firm's Toansa, India, facility. As noted by Bloomberg, this is now the fourth Ranbaxy manufacturing site that's a no-go in terms of providing products to the US. The latest reason: FDA inspectors found workers manipulated testing results so that failed drugs passed testing requirements.

The FDA ban's reach is pretty substantial because it bars fully manufactured drugs from entering the US, in addition to preventing US facilities from incorporating active ingredients from the facility into US-produced items.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters